Introduction
Nitrous oxide (N2O), commonly known as laughing gas, has gained popularity as a recreational drug in recent years, particularly among adults under 30 years of age [1]. Traditionally used for analgesia and sedation, N2O induces rapid sedation, euphoria, and, occasionally, hallucinogenic effects. The effects are short-lived, leading to repeated inhalations from a balloon to increase cumulative drug exposure. Some studies have reported up to 10 balloons of N2O used per episode [2-5]. High levels of N2O can lead to toxicity through various mechanisms, with vitamin B12 depletion emerging as a key factor [5]. Here, we present the case of a 27-year-old female who presented with gait ataxia and abnormal sensation found to have laughing gas-induced subacute combined degeneration from nitrous oxide. Clinicians should be aware of this emerging recreational drug as an important cause of new-onset neurological impairment.
Case presentation
A 27-year-old female with a past medical history of anxiety, depression, and opioid use disorder was brought by Emergency Medical Services with an inability to stand, lower extremity paresthesias, and gait instability. Starting two months ago, she stated that her legs would intermittently “fall asleep.” One month later, she developed paresthesia in both lower extremities. She reported associated fatigue and brain fog.
In the week before admission, her paresthesia worsened to the point where she could not walk without support. On the day of admission, her symptoms progressed to a complete loss of sensation in her legs and an inability to stand, prompting her to seek medical attention.
Her social history revealed daily consumption of about five alcoholic drinks and regular inhalation of N2O canisters. She initially began recreational inhalation of N2O six months before admission and reported a gradual increase in the quantity inhaled. Around the time her neurological symptoms began (two months before admission), she inhaled approximately 320 g of N2O per month (40 N2O canisters in the month). In the days leading up to her admission, her N2O inhalation had increased significantly, reaching around 2,560 g over six hours each day (approximately 320 N2O canisters over six hours each day).
On physical examination, she appeared in no acute distress. Oropharynx examination revealed a darkened, smooth red tongue. Neurological evaluation of the dorsal columns revealed a positive Romberg sign and ataxic gait. Additionally, sensory deficits included symmetric paresthesia distally from the umbilicus, reduced light touch and pinprick sensation throughout both upper and lower extremities without a clear sensory level, and bilateral pronator drift. Finger-to-nose testing revealed a serpentine pattern. Reflexes were 1+ and symmetric throughout. Cranial nerves II-XII were intact, and the Babinski sign was absent. Motor strength was 5/5 in all extremities.
On admission, laboratory data revealed a low vitamin B12 level (78 pg/mL, reference range: 180-914 pg/mL), high methylmalonic acid (MMA) level (4,137 nmol/L, reference range: 0-378 nmol/L), and normocytic anemia (Table 1). The urine drug screen was positive for benzodiazepines but negative for opioids, barbiturates, PCP, amphetamines, cocaine, cannabinoids, and alcohol. Syphilis was not checked as the patient was not sexually active. The patient denied alcohol as well as intravenous and other recreational drug use.
Table 1
Laboratory data.
H: high values of laboratory data; L: low values of laboratory data
Values | Reference range | |
Sodium | 138 | 136–145 mEq/L |
Potassium | 3.8 | 3.6–5.1 mEq/L |
Chloride | 105 | 101–111 mEQ/L |
Carbon dioxide | 26 | 22–32 mEq/L |
Anion gap | 7 | 3–13 |
Glucose | 106 (H) | 70–100 mg/dL |
Creatinine | 0.6 (L) | 0.7–1.2 mg/dL |
Calcium | 8.8 (L) | 8.9–10.3 mg/dL |
Total protein | 7.3 | 6.1–8.0 g/dL |
Albumin | 3.8 | 3.4–4.8 g/dL |
Total bilirubin | 1.1 (H) | <1.0 mg/dL |
Aspartate transaminase | 21 | <35 U/L |
Alanine transaminase | 22 | 10–63 U/L |
Alkaline phosphatase | 50 | 32–101 U/L |
C-reactive protein | 5.2 (H) | 0–1 mg/dL |
Folic acid | 16.2 | >5.9 ng/mL |
Magnesium | 2.2 | 1.8–2.5 mg/dL |
Thyroid-stimulating hormone | 1.41 | 0.34–5.60 mU/L |
Vitamin B12 | 78 (L) | 180–914 pg/mL |
Methylmalonic acid | 4,137 (H) | 0–378 nmol/L |
White blood cell | 6.8 | 4.0–15.7 k/mm3 |
Hemoglobin | 10.7 (L) | 13.5–16.5 g/dL |
Mean corpuscular volume | 94 | 80–95 fL |
Platelet | 274 | 135–350 k/mm3 |
A1c | 5.0 | 4.8–6.0% |
Erythrocyte sedimentation rate | 26 (H) | 9–20 mm/hour |
A non-contrast CT scan of the head showed no acute changes, and an MRI of the brain with and without contrast was also unremarkable. However, further imaging with MRI of the cervical and thoracic spine with and without contrast revealed a signal abnormality within the dorsal columns of the spinal cord, most severe throughout the upper cervical spinal cord extending from C2 through C5-C6 (Figures 1, 2). These findings were highly suspicious for subacute combined degeneration.
Figure 1
Laughing gas-induced subacute combined generation from nitrous oxide.
MRI of the cervical and thoracic spine with and without contrast revealed a T2 hyperintensity (arrows) within the dorsal columns of the spinal cord, most severe throughout the upper cervical spinal cord extending from C2 through C5-C6.
Figure 2
T2 hyperintensity most prominent in the dorsal columns suggestive of subacute combined degeneration.
MRI of the cervical spine (Axial, T2 fast spin echo) at the C2-C3 level showing T2 hyperintensity within the dorsal columns.
The patient began daily intramuscular vitamin B12 replacement with 1,000 µg weekly and was discharged from the hospital for physical rehabilitation and close neurology follow-up as an outpatient. Within three months of discontinuing N2O inhalation and receiving vitamin B12 supplementation, the patient experienced significant improvement in sensory and motor function, including regaining the ability to walk.
Discussion
N2O, or laughing gas, has gained recognition as a recreational drug in recent years, particularly among 16- to 24-year-olds, where it ranks as the second most-used drug behind cannabis in the United Kingdom [1]. High levels of N2O lead to toxicity through multiple mechanisms, with vitamin B12 depletion as a driving factor. Patients at risk for vitamin B12 deficiency have a lower threshold for N2O-induced toxicity [2].
Vitamin B12 is inactivated in N2O toxicity through the irreversible binding of N2O to the cobalt ion in vitamin B12 [3]. Normally, vitamin B12 is a cofactor for methionine synthase and methylmalonyl-CoA mutase. Dysfunction of these enzymes due to vitamin B12 inactivation leads to neurological and hematological abnormalities through malfunctioning catabolism of protein and fatty acids.
In fatty acid oxidation, methylmalonyl-CoA is converted to succinyl-CoA by methylmalonyl-CoA mutase, which uses vitamin B12 as a cofactor. When vitamin B12 is depleted, methylmalonyl-CoA mutase becomes dysfunctional. This leads to decreased succinyl-CoA synthesis and increased MMA, the precursor to methylmalonyl-CoA. Excess MMA leads to neurodegeneration by impairing spinal cord myelinization. Proposed mechanisms include inhibition of complex II, which is involved in the tricarboxylic acid (TCA) cycle and mitochondrial electron transport chain, decreased TCA activity due to reduced succinyl-CoA substrate, and synergistic excitotoxicity [4]. A recent study showed that patients with N2O overdose exhibited more prominent axonal dysfunction than those with vitamin B12 deficiency alone, suggesting another mechanism contributing to N2O-induced neurotoxicity [5].
In addition to neurological dysfunction, vitamin B12 deficiency leads to hematologic abnormalities through the dysfunction of methionine synthase. This enzyme uses methyl tetrahydrofolate (THF) and vitamin B12 as cofactors to convert homocysteine to methionine. During this process, methyl-THF is converted back to THF, which is a substrate required for DNA synthesis. If THF cannot be regenerated, as in vitamin B12 deficiency, DNA synthesis will be impaired. This results in ineffective erythropoiesis, characterized by defective DNA synthesis leading to megaloblastic transformation and intramedullary hemolysis [5]. Although erythroid hyperplasia occurs, the erythroid cells do not mature normally and subsequently die in the bone marrow. This can lead to a combination of megaloblastic anemia and cytopenias. Additionally, elevated homocysteine levels increase cardiovascular risk. Hyperhomocysteinuria elevates the risk of thrombosis and atherosclerosis, potentially causing stroke and myocardial infarction [6].
A thorough history is critical in making a diagnosis. Clinical features include hematological, neuropsychiatric, thrombotic, and cutaneous presentations of N2O overdose [7]. N2O has also been hypothesized to inhibit responses to hypoxia and hypercapnia, which has resulted in mortality [8]. The analgesic effect of N2O involves several neuromodulators in the spinal cord and resembles that of opioids. Moreover, N2O’s anxiolytic effect may be due to its similarity to benzodiazepines, potentially binding to select subunits of the GABA (A) receptors. This may also contribute to its anesthetic effect, with possible involvement of the NMDA receptor [9].
Laboratory tests may reveal features suggestive of vitamin B12 deficiency. A vitamin B12 level is easy to check and should be measured. If there is uncertainty, measuring MMA may help, as elevated levels are exclusive to B12 deficiency compared to other nutritional deficiencies such as folate deficiency [4]. Features of intramedullary hemolysis, such as elevated lactate dehydrogenase, low haptoglobin, and indirect hyperbilirubinemia, may also be observed [9]. A complete blood count may show macrocytic anemia due to megaloblastic transformation.
Radiographic findings may include signal abnormalities within the dorsal columns of the spinal cord, particularly in the cervical and thoracic regions [3]. Demyelination in the spinal cerebellar tracts, corticospinal tracts, and dorsal columns leads to the host of symptoms seen in subacute combined degeneration. Patients will present with ataxia and paresthesia as seen in this patient, as well as impaired proprioception and altered sensorium. Dementia can be seen in the elderly population presenting with subacute combined degeneration [5].
Treatment involves repleting vitamin B12, which is typically accomplished with B12 injections, and N2O cessation. Monitoring for B12 injection-induced hypokalemia during the first 48 hours of treatment is important, as new red blood cell production after providing the necessary materials for DNA synthesis may lead to potassium uptake into cells [2]. Aggressive vitamin B12 repletion and drug abstinence can reverse neurological impairment and improve functional outcomes, as seen in this case.
Conclusions
We present a rare case of subacute combined degeneration induced by N2O overdose. Clinicians should consider this emerging recreational drug-related cause of new neurological deficits in their differential diagnosis. Patients should be counseled on the importance of discontinuing N2O use and promptly starting vitamin B12 repletion to reverse neurological symptoms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2024, Rao et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Laughing gas is becoming increasingly popular as a recreational drug of choice, particularly among young adults. Nitrous oxide, the toxic component of laughing gas, can cause neuronal injury when used in high doses. Through multiple mechanisms, nitrous oxide leads to B12 depletion and subsequent demyelination, particularly in the spinal cord. Here, we present the case of a 27-year-old female who presented with ataxia and was found to have laughing gas-induced subacute combined degeneration from nitrous oxide. After aggressive vitamin B12 repletion and laughing gas cessation for three months, the patient improved.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer